To evaluate the clinical curative effect of torasemide plus human blood albumin for the treatment of cirrhosis ascites.

Atotal of 70 cases of patients with liver cirrhosis ascites were selected as the research objects that were treated between August 2014 and March 2014 in Huaiji County People’s Hospital, and a retrospective case-control study was carried out. Cases were chosen according to the single and double number methods and divided into observation group and control group, each group of 35 cases. On the basis of routine therapy, observation group of patients were treated with torasemide joint human blood albumin, and control group patients with torasemide only, for 1 week. Abdominal distension relief time, ascites and daily urine output, and serum Na + and K + concentration difference after treatment were observed in the patients between the two groups.

The abdominal distension relief time [d] (3.1-1.5) and ascites decreased time [(4.2+ 1.8)d] in the observation group were less than the control group patients [(4.5+ 1.3) d, (6.1+ 2.3) d], with statistically significant difference (all P<0.05). Observation group of patients had more average daily urine output [(2137.4+ 252.6) mL] than the control group patients [(1 529.6+ 217.3) mL], with statistically significant difference (P<0.05). After comparison between the two groups of patients, serum Na⁺ and K⁺ concentration had no statistically significant difference (P>0.05).

Joint use of torasemide and blood albumin for treatment of liver cirrhosis ascites can have the effect of synergies and improve the efficacy of clinical treatment, but further popularization and clinical application are needed.